Caffeine and anxiety: a multimodal PET/fMRI study of panic disorder
- Time period:
- 1 January 2018 – 31 December 2024
- Project leader:
- Andreas Frick
- Project member:
- Gunnar Antoni, Johan Wikström, Mark Lubberink, Kurt Wahlstedt
- Funder:
- Swedish Research Council
- Type of award:
- Project grant
- Total funding:
- 4,200,000 SEK
Anxiety disorders such as panic disorder are common and cause considerable individual suffering and high societal costs. Current treatment options leave a substantial proportion of patients suffering, urging the discovery of novel anti-anxiety treatments. In this respect, brain adenosine A1 and A2A receptors may be potential targets. Animal studies have linked fear-related behavior to reduced signaling at A1 receptors and increased signaling at A2A receptors, and in humans, the A1 and A2A antagonist caffeine can induce increased anxiety, occurrence of panic attacks, and elevated threat-related activity in the amygdala. In this project, we will test the hypotheses that adenosine A1 and A2A receptors are 1) affected in panic disorder and 2) modulate subjective anxiety and anxiety-related neural activity. State-of-the-art positron emission tomography and functional magnetic resonance imaging of anxiety-related processing in conjunction with a caffeine challenge will be conducted in thirty individuals with panic disorder and thirty healthy controls. The project will run for four years: 2018: applications of approval, implementation of imaging paradigms, and participant recruitment; 2019-2020: data collection and initial data analyses; 2021: data analyses and results reporting. The project has the potential to identify novel biomarkers and mechanistically informed treatment targets of excessive anxiety, and may thus have direct implications for clinical practice.